Brod, Meryl http://orcid.org/0000-0002-0663-5838
Rasmussen, Michael Højby
Alolga, Suzanne
Beck, Jane F.
Bushnell, Donald M. http://orcid.org/0000-0001-9226-1678
Lee, Kai Wai
Maniatis, Aristides http://orcid.org/0000-0002-6705-8579
Clinical trials referenced in this document:
Documents that mention this clinical trial
Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
https://doi.org/10.1007/s41669-022-00373-z
Funding for this research was provided by:
Novo Nordisk
Article History
Accepted: 8 September 2022
First Online: 18 October 2022
Declarations
:
: MB, MHR, KWL, SA, and JFB contributed to the study design and analysis and participated in manuscript preparation. DMB conducted analysis and participated in manuscript preparation. AM contributed to manuscript preparation and intellectual content. All authors read and approved the final manuscript.
: This research was supported by Novo Nordisk.
: M. Brod, S. Alolga, J.F. Beck, and D.M. Bushnell are paid consultants to the pharmaceutical industry, including Novo Nordisk. M. Højby Rasmussen is an employee of Novo Nordisk A/S and owns stock in the company. K.W. Lee was an employee of Novo Nordisk A/S when the research was conducted. A. Maniatis is a principal investigator for Novo Nordisk, Ascendis, Pfizer/OPKO, Genentech, and Sandoz.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Copernicus Group IRB, Tracking #: TBG1-15-428) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all respondents who participated in the study.
: Not applicable.
: The data for the research presented in the publication may be available on a case-by-case basis, for reasonable requests, from the corresponding author.
: Not applicable.